Quick Answer
Cellectar Biosciences, Inc. reported Operating Income Loss of -$22.98 million for the year ending 2025.
- Cellectar Biosciences, Inc. showed an increase of +55.6% in Operating Income Loss from 2024 to 2025.
- This data is from Cellectar Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: -$2.05 million | Q1 2013: -$2.71 million | Q2 2013: -$2.72 million | Q3 2013: -$2.91 million | Q1 2014: -$2.82 million | Q2 2014: -$2.55 million | Q3 2014: -$2.27 million | Q1 2015: -$2.59 million | Q2 2015: -$2.29 million | Q3 2015: -$2.09 million | Q1 2016: -$2.00 million | Q2 2016: -$2.33 million | Q3 2016: -$2.47 million | Q1 2017: -$2.81 million | Q2 2017: -$3.22 million | Q3 2017: -$3.48 million | Q1 2018: -$3.45 million | Q2 2018: -$2.90 million | Q3 2018: -$3.09 million | Q1 2019: -$3.63 million | Q2 2019: -$3.20 million | Q3 2019: -$3.96 million | Q1 2020: -$3.96 million | Q2 2020: -$3.62 million | Q3 2020: -$3.91 million | Q1 2021: -$6.36 million | Q2 2021: -$6.03 million | Q3 2021: -$5.82 million | Q1 2022: -$6.14 million | Q2 2022: -$7.44 million | Q3 2022: -$7.82 million | Q1 2023: -$8.71 million | Q2 2023: -$8.29 million | Q3 2023: -$9.41 million | Q1 2024: -$12.00 million | Q2 2024: -$13.70 million | Q3 2024: -$13.33 million | Q1 2025: -$6.40 million | Q2 2025: -$6.04 million | Q3 2025: -$4.85 million.
- Over the full 16 years of available data (2010 to 2025), Cellectar Biosciences, Inc.'s Operating Income Loss has declined by 448.0%.
- Historical annual values: Fiscal year 2025: -$22.98 million | Fiscal year 2024: -$51.78 million | Fiscal year 2023: -$38.96 million | Fiscal year 2022: -$28.81 million | Fiscal year 2021: -$24.13 million | Fiscal year 2020: -$15.29 million | Fiscal year 2019: -$14.18 million | Fiscal year 2018: -$13.33 million | Fiscal year 2017: -$13.60 million | Fiscal year 2016: -$9.45 million | Fiscal year 2015: -$8.76 million | Fiscal year 2014: -$9.89 million | Fiscal year 2013: -$12.40 million | Fiscal year 2012: -$8.75 million | Fiscal year 2011: -$7.04 million | Fiscal year 2010: -$4.19 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: